UNSPSC 51432601: Lidoflazine

This classification denotes a calcium channel blocker with the molecular formula C30H35F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4ZHN3HBTE, chemically known as 4-(4,4-bis(p-fluorophenyl)butyl)-1-piperazineaceto-2,6-xylidide but generally known as lidoflazine, which bears US NIH Compound Identifier 3926. European Medicines Agency schedules Lidoflazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08509MIG. The term LIDOFLAZINE is an International Non-Proprietary Name.

UNSPSC 51432601 Lidoflazine, a Commodity code, nominally covers a single pharmaceutical ingredient, but recent state and local solicitations using this code actually procure broader advanced life support medications and multi-source generic pharmaceuticals for fire rescue, health and human services, and cooperative purchasing programs. The City of Tampa's fire rescue division, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing-body mix—municipal fire services, state health agencies, and multi-state cooperative purchasing consortia sourcing for their member jurisdictions. The scope of work spans emergency medical supply provision (specific vials and injections for paramedic use), state pharmacy benefit program modernization and direct-to-manufacturer contracting strategies, and cooperative-purchasing pharmaceutical aggregation across state and local health systems.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 on April 24, 2026, for advanced life support medications (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem) with a response deadline of April 8, 2026, an estimated contract value of $40,000, a one-year term with two optional one-year renewals plus discretionary 30-day extensions, and a 5 percent SLBE bid discount capped at $10,000. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels—an exploratory information-gathering phase informing future formal procurement. MMCAP posted an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with response due March 26, 2026, requiring NDC-specific pricing, cGMP and DSCSA compliance, relationships with authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), a two-year contract term for new vendors, and performance penalties of $200 to $1,500 per violation.